Literature DB >> 7794067

Decreased mortality of severe acute pancreatitis after proximal cytokine blockade.

J G Norman1, M G Franz, G S Fink, J Messina, P J Fabri, W R Gower, L C Carey.   

Abstract

OBJECTIVE: This study determined the ability of interleukin-1 receptor antagonist (IL-1ra) to decrease the mortality of experimental acute pancreatitis. The response of the inflammatory cytokine cascade and its subsequent effects on pancreatic morphology were measured to determine the role of these peptides in mediating pancreatic injury. SUMMARY BACKGROUND DATA: Previous studies have shown that proinflammatory cytokines are produced in large amounts during acute pancreatitis and that blockade at the level of the IL-1 receptor significantly decreases intrinsic pancreatic damage. The subsequent effect on survival is not known.
METHODS: A lethal form of acute hemorrhagic necrotizing pancreatitis was induced in young female mice by feeding a choline-deficient, ethionine supplemented (CDE) diet for 72 hours. For determination of mortality, the animals were divided into 3 groups of 45 animals each: control subjects received 100/microL normal saline intraperitoneally every 6 hours for 5 days; IL-1ra early mice received recombinant interleukin-1 receptor antagonist 15 mg/kg intraperitoneally every 6 hours for 5 days beginning at time 0; IL-1ra late mice received IL-1ra 15 mg/kg intraperitoneally every 6 hours for 3.5 days beginning 1.5 days after introduction of the CDE diet. A parallel experiment was conducted simultaneously with a minimum of 29 animals per group, which were sacrificed daily for comparisons of serum amylase, lipase, IL-1, IL-6, tumor necrosis factor-alpha, IL-1ra, pancreatic wet weight, and blind histopathologic grading.
RESULTS: The 10-day mortality in the untreated control group was 73%. Early and late IL-1ra administration resulted in decreases of mortality to 44% and 51%, respectively (both p < 0.001). Interleukin-1 antagonism also was associated with a significant attenuation in the rise in pancreatic wet weight and serum amylase and lipase in both early and late IL-1ra groups (all p < 0.05). All control animals developed a rapid elevation of the inflammatory cytokines, with maximal levels reached on day 3. The IL-1ra-treated animals, however, demonstrated a blunted rise of these mediators (all p < 0.05). Blind histologic grading revealed an overall decrease in the severity of pancreatitis in those animals receiving the antagonist.
CONCLUSIONS: Early or late blockade of the cytokine cascade at the level of the IL-1 receptor significantly decreases the mortality of severe acute pancreatitis. The mechanism by which this is accomplished appears to include attenuation of systemic inflammatory cytokines and decreased pancreatic destruction.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7794067      PMCID: PMC1234684          DOI: 10.1097/00000658-199506000-00002

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  22 in total

1.  Beneficial effects of cholecystokinin-receptor blockade and inhibition of proteolytic enzyme activity in experimental acute hemorrhagic pancreatitis in mice. Evidence for cholecystokinin as a major factor in the development of acute pancreatitis.

Authors:  C Niederau; R A Liddle; L D Ferrell; J H Grendell
Journal:  J Clin Invest       Date:  1986-10       Impact factor: 14.808

2.  Histologic and biochemical alterations in experimental acute pancreatitis induced by supramaximal caerulein stimulation.

Authors:  S Tani; M Otsuki; H Itoh; M Fujii; T Nakamura; T Oka; S Baba
Journal:  Int J Pancreatol       Date:  1987 Oct-Dec

Review 3.  Why should internists be interested in interleukin-1?

Authors:  R Neta; J J Oppenheim
Journal:  Ann Intern Med       Date:  1988-07-01       Impact factor: 25.391

4.  Acute hemorrhagic pancreatitis (massive necrosis) with fat necrosis induced in mice by DL-ethionine fed with a choline-deficient diet.

Authors:  B Lombardi; L W Estes; D S Longnecker
Journal:  Am J Pathol       Date:  1975-06       Impact factor: 4.307

Review 5.  Interleukin 1: the first interleukin.

Authors:  F S di Giovine; G W Duff
Journal:  Immunol Today       Date:  1990-01

6.  Interleukin-1 (IL-1) receptor antagonist prevents Staphylococcus epidermidis-induced hypotension and reduces circulating levels of tumor necrosis factor and IL-1 beta in rabbits.

Authors:  K Aiura; J A Gelfand; J F Burke; R C Thompson; C A Dinarello
Journal:  Infect Immun       Date:  1993-08       Impact factor: 3.441

Review 7.  Biology of interleukin 1.

Authors:  C A Dinarello
Journal:  FASEB J       Date:  1988-02       Impact factor: 5.191

8.  Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition.

Authors:  S Okusawa; J A Gelfand; T Ikejima; R J Connolly; C A Dinarello
Journal:  J Clin Invest       Date:  1988-04       Impact factor: 14.808

9.  Interleukin-1 receptor antagonist decreases severity of experimental acute pancreatitis.

Authors:  J Norman; M Franz; J Messina; A Riker; P J Fabri; A S Rosemurgy; W R Gower
Journal:  Surgery       Date:  1995-06       Impact factor: 3.982

10.  Interleukin 1 potentiates the lethal effect of tumor necrosis factor alpha/cachectin in mice.

Authors:  A Waage; T Espevik
Journal:  J Exp Med       Date:  1988-06-01       Impact factor: 14.307

View more
  37 in total

1.  Influence of continuous veno-venous hemofiltration on the course of acute pancreatitis.

Authors:  Hong-Li Jiang; Wu-Jun Xue; Da-Qing Li; Ai-Ping Yin; Xia Xin; Chun-Mei Li; Ju-Lin Gao
Journal:  World J Gastroenterol       Date:  2005-08-21       Impact factor: 5.742

2.  Pancreatic acinar cells produce, release, and respond to tumor necrosis factor-alpha. Role in regulating cell death and pancreatitis.

Authors:  A S Gukovskaya; I Gukovsky; V Zaninovic; M Song; D Sandoval; S Gukovsky; S J Pandol
Journal:  J Clin Invest       Date:  1997-10-01       Impact factor: 14.808

3.  Therapeutic application of caspase 1/interleukin-1beta-converting enzyme inhibitor decreases the death rate in severe acute experimental pancreatitis.

Authors:  Adam S Paszkowski; Bettina Rau; Jens M Mayer; Peter Möller; Hans G Beger
Journal:  Ann Surg       Date:  2002-01       Impact factor: 12.969

Review 4.  Acute pancreatitis at the beginning of the 21st century: the state of the art.

Authors:  Alfredo F Tonsi; Matilde Bacchion; Stefano Crippa; Giuseppe Malleo; Claudio Bassi
Journal:  World J Gastroenterol       Date:  2009-06-28       Impact factor: 5.742

5.  Multisystemic production of interleukin 10 limits the severity of acute pancreatitis in mice.

Authors:  J L Van Laethem; R Eskinazi; H Louis; F Rickaert; P Robberecht; J Devière
Journal:  Gut       Date:  1998-09       Impact factor: 23.059

6.  Peritoneal lavage reduces lipopolysaccharide-induced elevation of serum TNF-alpha and IL-6 mortality in mice.

Authors:  K Zhao; I Kirman; I Tschepen; R Schwab; M E Weksler
Journal:  Inflammation       Date:  1997-08       Impact factor: 4.092

7.  Role of cytokines and their inhibitors in acute pancreatitis.

Authors:  A Kingsnorth
Journal:  Gut       Date:  1997-01       Impact factor: 23.059

8.  Changes in gene expression of tumor necrosis factor alpha and interleukin 6 in a canine model of caerulein-induced pancreatitis.

Authors:  Ruhui Song; Dohyeon Yu; Jinho Park
Journal:  Can J Vet Res       Date:  2016-07       Impact factor: 1.310

9.  Dexamethasone and dextran 40 treatment of 32 patients with severe acute pancreatitis.

Authors:  Zi-Fa Wang; Chang Liu; Yi Lu; Rui Dong; Jun Xu; Liang Yu; Ying-Min Yao; Qing-Guang Liu; Cheng-En Pan
Journal:  World J Gastroenterol       Date:  2004-05-01       Impact factor: 5.742

10.  Cost-effectiveness analysis of early veno-venous hemofiltration for severe acute pancreatitis in China.

Authors:  Kun Jiang; Xin-Zu Chen; Qing Xia; Wen-Fu Tang; Lei Wang
Journal:  World J Gastroenterol       Date:  2008-03-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.